When does Follow-up on Adverse Events Improve the Understanding of Medicine and Vaccine Safety? Insights from Global Expert Perspectives
Drug Safety · 2026
DOI: 10.1007/s40264-026-01691-5 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Safety, 2026. Verfasst von Vijay Kara und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaco-Therapy, Epidemiology and Economics, Groningen Research Institute of Pharmacy (GRIP), University of Groningen, Groningen, The …. Hauptthemen laut MEDLINE: Vaccines, Pharmacovigilance, Adverse Drug Reaction Reporting Systems, Drug-Related Side Effects and Adverse Reactions. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Themen: Patientensicherheit
Abstract (Originalsprache)
INTRODUCTION AND OBJECTIVE: Adverse events (AEs) reported with medicines and vaccines form the foundation of pharmacovigilance (PV), enabling the detection, assessment, and prevention of drug-related risks. Initial AE reports often lack relevant clinical detail, limiting their utility. Follow-up is used to obtain additional information but is resource-intensive. Spontaneous reporting systems receive large volumes of reports and follow-up yields additional information in only a proportion of cases. Given these volumes and variable yield, it is important to define when follow-up is most likely to add value and when it is likely to be low-yield or futile. This study aimed to identify scenarios where follow-up on AEs meaningfully improves the understanding of medicine and vaccine safety, and to delineate circumstances when it may be less beneficial or futile. METHODS: A Delphi based methodology was used to systematically gather expert consensus on scenarios in which follow-up of AE reports enhances the understanding of medicine and vaccine safety. RESULTS: Data saturation was achieved after ten interviews. Panel members identified three primary scenarios in which follow-up adds value in PV: supporting causality assessment, strengthening signal detection and monitoring, and informing risk management and public health actions. They saw questionable or no value in follow up of well-characterised labelled events, cases in which the reporter cannot be contacted or did not consent to further contact, and settings where additional data were unlikely to alter benefit-risk. CONCLUSION: This study characterises expert perspectives on when follow-up activities are most likely to provide actionable value. Our results indicate that follow-up improves understanding when it resolves clinical uncertainty, but is inefficient when pursued without regard to impact, supporting a shift to proportionate, purpose-driven follow-up strategies for consistent and efficient use of resources including criteria for prioritisation and de-prioritisation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmaco-Therapy, Epidemiology and Economics, Groningen Research Institute of Pharmacy (GRIP), University of Groningen, Groningen, The Netherlands. v.kara@rug.nl.
- GSK, London, UK. v.kara@rug.nl.
- Department of Pharmaco-Therapy, Epidemiology and Economics, Groningen Research Institute of Pharmacy (GRIP), University of Groningen, Groningen, The Netherlands.
- Netherlands Pharmacovigilance Centre Lareb, 's-Hertogenbosch, The Netherlands.
- Iraqi Pharmacovigilance Centre, Ministry of Health, Baghdad, Iraq.
- Merck KGaA, Darmstadt, Germany.
Zitieren
APA
Kara, V., Van Hunsel, F., Younus, M., Hauben, M., Bate, A., & van Puijenbroek, E. (2026). When does Follow-up on Adverse Events Improve the Understanding of Medicine and Vaccine Safety? Insights from Global Expert Perspectives. Drug Safety. https://doi.org/10.1007/s40264-026-01691-5
Vancouver
Kara V, Van Hunsel F, Younus M, Hauben M, Bate A, van Puijenbroek E. When does Follow-up on Adverse Events Improve the Understanding of Medicine and Vaccine Safety? Insights from Global Expert Perspectives. Drug Safety. 2026. doi:10.1007/s40264-026-01691-5
BibTeX
@article{Kara2026,
author = {Kara, Vijay and Van Hunsel, Florence and Younus, Manal and Hauben, Manfred and Bate, Andrew and van Puijenbroek, Eugène},
title = {When does Follow-up on Adverse Events Improve the Understanding of Medicine and Vaccine Safety? Insights from Global Expert Perspectives},
journal = {Drug Safety},
year = {2026},
doi = {10.1007/s40264-026-01691-5}
}
EUVIMED